Ocular Therapeutix, Inc. OCUL
At closeNov 10, 2026, 4:27 PM EST
After hours · Nov 10, 4:27 PM ET
- YTD
- -45.55%
- 1 year
- -38.97%
- Market cap
- 1.45B
- Revenue (ttm)
- 50.38M
- EPS (ttm)
- -1.44
- Shares out
- 220.02M
- Forward P/E
- -4.14
- YTD return
- -45.55%
- 1-year return
- -38.97%
- Volume
- 2.66M
- Avg volume
- 3.12M
- Open
- 6.85
- Previous close
- 6.85
- Day's range
- 6.60 – 6.87
- 52-week range
- 6.29 – 16.11
- Beta
- 1.22
- Analysts
- Strong Buy
- Price target
- 25.45 (+285.1%)
- Earnings date
- Feb 4, 2027
5D -0.46 (-6.51%)
Key statistics
- Enterprise value
- 1.06B
- PEG ratio
- 0.00
- Price / sales
- 28.87
- Price / book
- 3.30
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -11.50%
- Free cash flow
- -159.98M
- Total cash
- 530.61M
- Total debt
- 80.01M
- Return on equity
- -93.48%
- Short % of float
- 15.43%
- 50-day average
- 8.33
- 200-day average
- 8.99
Analyst view
Consensus: strong buy
- Target (low)
- 14.00
- Target (mean)
- 25.45
- Target (high)
- 34.00
- Strong buy4
- Buy8
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate -0.40776.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 30, 2026 | -0.37 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | -0.36348 | -0.42 | -0.06 | -15.55% |
| Aug 3, 2026 | Jun 30, 2026 | -0.39545 | -0.35 | +0.05 | +11.49% |
| May 5, 2026 | Mar 31, 2026 | -0.32 | -0.41 | -0.09 | -28.12% |
| Feb 5, 2026 | Dec 31, 2025 | -0.33 | -0.29 | +0.04 | +12.12% |
| Nov 4, 2025 | Sep 30, 2025 | -0.39 | -0.37 | +0.02 | +5.13% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 19, 2026 | Needham | reit | Buy | Buy |
| Oct 12, 2026 | UBS | init | — | Buy |
| Oct 2, 2026 | Chardan Capital | main | Buy | Buy |
| Sep 29, 2026 | Needham | reit | Buy | Buy |
| Sep 16, 2026 | Chardan Capital | main | Buy | Buy |
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- ocutx.com
News
HC Wainwright & Co. Maintains Buy on Ocular Therapeutix, Raises Price Target to $28 
Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript 
What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call 
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates 
Ocular Therapeutix Q3 2026 Earnings Call Transcript 
Ocular Therapeutix Q3 EPS $(0.42) Misses $(0.36) Estimate, Sales $12.874M Miss $14.339M Estimate 
Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights 
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
Critical Analysis: Lyra Therapeutics (OTCMKTS:LYRA) and Ocular Therapeutix (NASDAQ:OCUL) 
Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026
Your note
Sign in to keep a note on OCUL — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERMAN TODD | Officer | Sale | Oct 7, 2026 | 140,484 |
| DUGEL PRAVIN U | Chief Executive Officer | Stock Gift | Aug 24, 2026 | 0 |
| HEIER JEFFREY S. | Officer | Sale | Oct 1, 2026 | 307,457 |
| KAISER PETER KAZUO | Officer | Sale | Oct 1, 2026 | 254,388 |
| LINDSTROM RICHARD L | Director | Stock Award(Grant) | Jun 9, 2026 | 260,933 |
| MEYERS STEVE LAWRENCE | Officer | Stock Award(Grant) | Jan 1, 2026 | 217,628 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.96% | 32,844,043 | 217.10M | Jun 29, 2026 |
| Deep Track Capital, Lp | 8.96% | 19,686,282 | 130.13M | Jun 29, 2026 |
| Blackrock Inc. | 8.82% | 19,376,555 | 128.08M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 5.71% | 12,540,000 | 82.89M | Jun 29, 2026 |
| Summer Road LLC | 5.68% | 12,463,296 | 82.38M | Sep 29, 2026 |
| Venrock Adviser, LLC | 4.71% | 10,346,926 | 68.39M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 4.46% | 9,804,363 | 64.81M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.01% | 6,616,995 | 43.74M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.53% | 5,562,722 | 36.77M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund | 1.25% | 2,751,674 | 18.19M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund | 1.12% | 2,461,078 | 16.27M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.03% | 2,261,254 | 14.95M | Aug 30, 2026 |